Betahistine for symptoms of vertigo

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 6, 2016, Pages

  Murdin, Louisa ^a,b   Hussain, Kiran ^a   Schilder, Anne G M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETAHISTINE;

BENIGN PAROXYSMAL POSITIONAL VERTIGO; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; META ANALYSIS; PALLIATIVE THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VERTIGO; VESTIBULAR TEST;

BENIGN PAROXYSMAL POSITIONAL VERTIGO; BETAHISTINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VERTIGO;

EID: 84976330183     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010696.pub2     Document Type: Review

References (70)

1. Burkin A. Betahistine treatment for Meniere's syndrome. Clinical Medicine 1967;74:41-8.
2. Canty P, Valentine J. Betahistine in peripheral vertigo: a double-blind, placebo-controlled, cross-over study of Serc versus placebo. Journal of Laryngology and Otology 1981;95:687-92.
3. Conraux C, Cellier D. Chronic vertigo sensations. Multi-centre randomised double-blind comparative study 8mg Serc vs placebo in patients suffering from chronic vertigo [Les sensations vertigineuses chroniques: efficacité de la betahistine prouvée dans un essai therapeutique en double aveugle]. Impact Medecin 1988;260:63-5.
4. Duphar . 77054 Betahistine dihydrochloride and peripheral vertigo: a double blind placebo-controlled trial in outpatients. Unpublished data 1983.
5. Duphar . H10800580M A prospectively randomised placebo controlled double blind parallel group study of betahistine dihydrochloride in patients presenting with vertigo and central signs on electronystagmography. Unpublished data 1984.
6. Duphar . H10802786F/M Double blind randomised multicentre study to compare Serc 8mg with placebo. Unpublished data 1989.
7. Duphar . H10803592F Double blind multicentre randomised comparative study of Serc 24mg vs placebo in two groups of patients with recurrent vertigo. Unpublished data 1997.
8. Duphar . H 108.906 A double blind placebo-controlled study with betahistine (Betaserc) in forms of vertigo eligible for drug treatment. Unpublished data 1990.
9. Fischer AJ, Van Elferen LWM. Betahistine in the treatment of paroxysmal attacks of vertigo. A double blind investigation [Betahistine bij de behandeling van aanyalsgewijs optredende duizeligheid. Een dubbelblind onderzoek]. JDR (J Drug Therapy Res) 1985;10:933-7.
10. Guneri EA, Kustutan O. The effects of betahistine in addition to Epley maneuver in posterior canal benign paroxysmal positional vertigo. Otolaryngology - Head and Neck Surgery 2012;146(1):104-8.
11. Legent F, Calais C, Cellier D. Trial of betahistine in paroxysmal vertigo [French]. Concours Medical 1988;110(29):2539-43.
12. Mira E, Guidetti G, Ghilardi L, Fattori B, Malannino N, Maiolino L, et al. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. European Archives of Oto-Rhino-Laryngology 2003;260(2):73-7.
13. Okamoto K, Hazeyama F, Taira T, Yoshida A, Onoda T. Therapeutic results of betahistine on Meniere's disease. Multi-variable analysis of the results of the double blind test and Fisher's evaluation method. Iryo 1968;22(5):650-66.
14. Oosterveld WJ, Blijleven W, van Elferen LWM. Betahistine versus placebo in paroxysmal vertigo; a double blind trial. Tijdschr Ther Geneesm Onderz 1989;14:122-6.
15. Otto V, Fischer B, Schwarz M, Baumann W, Preibisch-Effenberger R. Treatment of vertebrobasilar insufficiency--associated vertigo with a fixed combination of cinnarizine and dimenhydrinate. International Tinnitus Journal 2008;14(1):57-67.
16. Ricci V, Sittoni V, Nicora M. Efficacy and safety of betahistine hydrochloride versus placebo in Meniere's disease [Valutazione terapeutica e tollerabilita del cloridrato di betaistina (microser) in confronto a placebo nella malattia di meniere]. Rivista Italiana di Ornitologia Audiologia e Foniatria 1987;7(3):347-50.
17. Salami A, Delle PM, Tinelli E, Jankowska B. Double blind study between betahistine hydrochloride and placebo in the treatment of Meniere's syndromes [Studio a doppia cecita tra cloridrato di betaistina e placebo nel trattamento delle sindromi menieriformi]. Il Valsalva 1984;60:302-12.
18. Bertrand RA. Méniére's disease: subjective and objective evaluation of medical treatment with betahistine HCl. Acta Oto-Laryngologica. Supplement 1972;305:48-69.
19. Elia JC. Double-blind evaluation of a new treatment for Meniere's syndrome. JAMA 1966;196:187-9.
20. Frew IJ, Menon GN. Betahistine hydrochloride in Méniére's disease. Postgraduate Medical Journal 1976;52(610):501-3.
21. Hommes OR. A study of the efficacy of betahistine in Méniére's syndrome. Acta Oto-Laryngologica. Supplement 1972;305:70-9.
22. Meyer ED. Treatment of Meniere disease with betahistine dimesilate (Aequamen)--double-blind study versus placebo (crossover). Laryngologie, Rhinologie, Otologie 1985;64(5):269-72.
23. Solvay Pharmaceuticals. A double-blind, placebo-controlled, randomized, clinical study of the effects of Betaserc® 24 mg (1 tablet b.i.d over 3 months) on vestibular compensation following vestibular neurotomy in patients with disabling Meniere's disease [completed]. http://clinicaltrials.gov/show/NCT00160238 2008.
24. NCT00474409 . A multicenter, placebo-controlled, double-blind study to evaluate the efficacy and safety of betahistine mesilate in the treatment of patients with vertigo caused by cerebral infarction in posterior circulation. http://clinicaltrials.gov/show/NCT00474409 2007 (accessed 5 August 2013).
25. Oosterveld WJ. Betahistine dihydrochloride in the treatment of vertigo of peripheral vestibular origin. A double-blind placebo-controlled study. Journal of Laryngology and Otology 1984;98(1):37-41.
26. Purohit SD, Jain DK, Agarwal S, Gupta ML, Sharma TN, Jain NK, et al. Betahistine dihydrochloride in the management of streptomycin induced vestibular damage (assessed by craniocorpography). Lung India 1988;6(2):61-4.
27. Redon C, Lopez C, Bernard-Demanze L, Dumitrescu M, Magnan J, Lacour M, et al. Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss. Journal of Clinical Pharmacology 2011;51(4):538-48.
28. Schmidt JT, Huizing EH. The clinical drug trial in Meniere's disease with emphasis on the effect of betahistine SR. Acta Oto-Laryngologica. Supplement 1992;497:1-189.
29. Singarelli S. Double-blind trial on the efficacy of betahistine hydrochloride in a group of outpatients with positional vertigo and tinnitus. Nuovo Archivio Italiano di Otologia Rinologia e Laringologia 1979;Suppl 7:69-72.
30. Verspeelt J, De Locht P, Amery WK. Postmarketing study of the use of flunarizine in vestibular vertigo and in migraine. European Journal of Clinical Pharmacology 1996;51:15-22.
31. Watanabe K, Fukami J, Yoshimoto H, Ueda M, Suzuki J. Evaluation of the effect of betahistine in Meniere's disease by double-blind test and multivariate analysis. Jibiinkoka 1967;39(11):1237-50.
32. Wilmot TJ, Menon GN. Betahistine in Meniere's disease. Journal of Laryngology and Otology 1976;90:833-40.
33. Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial - BETAVEST. EUCTR. Available from: http://apps.who.int/trialsearch/trial.aspx?trialid=EUCTR2009-013702-14-DE 2010 (accessed 5 August 2013). [EUCTR2009-013702-14-DE]
34. Medical treatment of Meniere's disease with betahistine: a placebo-controlled, dose-finding study. ISRCTN 2007 (accessed 5 August 2013). [http://www.controlled-trials.com/ISRCTN44359668/]
35. AAO-HNS . Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere's disease, American Academy of Otolaryngology - Head and Neck Foundation. Otolaryngology - Head and Neck Surgery 1995;113:181-5.
36. Adrion C, Fischer C S, Wagner J, Gurkov R, Mansmann U, Strupp M. Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ 2016;352:h6816.
37. Agus S, Benecke H, Thum C, Strupp M. Clinical and demographic features of vertigo: findings from the REVERT registry. Frontiers in Neurology 2013;4:48.
38. Barak N. Betahistine: what's new on the agenda?. Expert Opinion on Investigational Drugs 2008;17:795-804.
39. Bisdorff A, Von Brevern M, Lempert T, Newman-Toker DE. Classification of vestibular symptoms: towards an international classification of vestibular disorders. Journal of Vestibular Research: Equilibrium & Orientation 2009;19:1-13.
40. Cohen HS, Kimball KT. Development of the vestibular disorders activities of daily living scale. Archives of Otolaryngology--Head & Neck Surgery 2000;126:881-7.
41. Della Pepa C, Guidetti G, Eandi M. Betahistine in the treatment of vertiginous syndromes: a meta-analysis. Acta Otorhinolaryngologica Italica 2006;26:208-15.
42. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
43. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
44. Hannaford PC, Simpson JA, Bisset AF, Davis A, McKerrow W, Mills R. The prevalence of ear, nose and throat problems in the community: results from a national cross-sectional postal survey in Scotland. Family Practice 2005;22:227-33.
45. Hilton M, Pinder D. The Epley (canalith repositioning) manoeuvre for benign paroxysmal positional vertigo. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD003162.pub3]
46. Hunt WT, Zimmermann EF, Hilton MP. Modifications of the Epley (canalith repositioning) manoeuvre for posterior canal benign paroxysmal positional vertigo (BPPV). Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD008675.pub2]
47. Ihler F, Bertlich M, Sharaf K, Strieth S, Strupp M, Canis M. Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo. PLoS One 2012;7:e39086.
48. Jacobson GP, Newman CW. The development of the Dizziness Handicap Inventory. Archives of Otolaryngology--Head and Neck Surgery 1990;116:424-7.
49. James A, Burton MJ. Betahistine for Ménière's disease or syndrome. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD001873]
50. Karatas M. Vascular vertigo: epidemiology and clinical syndromes. Neurologist 2010;17:1-10.
51. Kruschinski C, Kersting M, Breull A, Kochen MM, Koschack J, Hummers-Pradier E. Frequency of dizziness-related diagnoses and prescriptions in a general practice database. Zeitschrift fur Evidenz Fortbildung und Qualitat im Gesundheitswesen 2008;102:313-9.
52. Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Carey J, et al. Vestibular migraine: diagnostic criteria. Journal of Vestibular Research: Equilibrium & Orientation 2012;22:167-72.
53. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD003225.pub2]
54. Lopez-Escamez JA, Carey J, Chung WH, Goebel JA, Magnusson M, Mandalà M, et al. Diagnostic criteria for Meniere's disease. Journal of Vestibular Research 2015;25(1):1-7.
55. Martinez DM. The effect of Serc (betahistine hydrochloride) on the circulation of the inner ear in experimental animals. Acta Oto-Laryngologica. Supplement 1972;305:29-47.
56. McDonnell MN, Hillier SL. Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD005397.pub4]
57. Megnigbeto CA, Sauvage JP, Launois R. The European Evaluation of Vertigo (EEV) scale: a clinical validation study. Revue de Laryngologie - Otologie - Rhinologie 2001;122:95-102.
58. Murdin L, Schilder AG. Epidemiology of balance symptoms and disorders in the community: a systematic review. Otology & Neurotology 2015;36(3):387-92. [DOI: 10.1097/MAO.0000000000000691]
59. Nauta JJ. Meta-analysis of clinical studies with betahistine in Meniere's disease and vestibular vertigo. European Archives of Oto-Rhino-Laryngology 2014;271(5):887-97.
60. Nazareth I, Yardley L, Owen N, Luxon L. Outcome of symptoms of dizziness in a general practice community sample. Family Practice 1999;16:616-8.
61. Neuhauser HK, von Brevern M, Radtke A, Lezius F, Feldmann M, Ziese T, et al. Epidemiology of vestibular vertigo: a neurotologic survey of the general population. Neurology 2005;65:898-904.
62. Newman-Toker DE, Dy FJ, Stanton VA, Zee DS, Calkins H, Robinson KA. How often is dizziness from primary cardiovascular disease true vertigo? A systematic review. Journal of General Internal Medicine 2008;23:2087.
63. Pathy J, Menon G, Reynolds A, Van Strik R. Betahistine hydrochloride (Serc) in cerebrovascular disease a placebo-controlled study. Age and Ageing 1977;6(3):179-84.
64. Ramos Alcocer R, Ledezma Rodríguez JG, Navas Romero A, Cardenas Nuñez JL, Rodríguez Montoya V, Deschamps JJ, et al. Use of betahistine in the treatment of peripheral vertigo. Acta Oto-Laryngologica 2015 Aug 6 [Epub ahead of print].
65. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
66. Strupp M, Brandt T. Peripheral vestibular disorders. Current Opinion in Neurology 2013;26:81-9.
67. Timmerman H. Pharmacotherapy of vertigo - any news to be expected?. Acta Oto-Laryngologica 1994;513:28-32.
68. Wiltink J, Tschan R, Michal M, Subic-Wrana C, Eckhardt-Henn A, Dieterich M, et al. Dizziness: anxiety, health care utilization and health behavior--results from a representative German community survey. Journal of Psychosomatic Research 2009;66:417-24.
69. Yardley L, Owen N, Nazareth I, Luxon L. Prevalence and presentation of dizziness in a general practice community sample of working age people. British Journal of General Practice 1998;48:1131-5.
70. Murdin L, Hussain K, Schilder AGM. Betahistine for symptoms of vertigo. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD010696]